Skip to main content

Table 5 Comparison between obese and non-obese patients (CHC and HCC)

From: Chronic hepatitis c genotype-4 infection: role of insulin resistance in hepatocellular carcinoma

Variables Obese
N = 42
N(%)
Non-obese
N = 58
N(%)
P-value
Age 60 (36-76) 57(34-73) 0.168
Biochemical tests Median(Range),    
ALT (IU/L) 60 (36-180) 60(25-103) 0.817
AST (IU/L) 93.5(34-310) 90(25-300) 0.115
T. Bil (mg/dL) 2.1(0.6-4.5) 1.9(0.5-6) 0.092
Albumin (g/dL) 3.1(1.6-4.2) 3.2(1.6-4.2) 0.262
INR 1.2(0.8-1.5) 1.1(0.7-1.5) <0.001
GGT (IU/L) 83.5(25-560) 71(15-500) 0.043
Fasting Glu (mg/dL) 190((96-890) 150 (76-870) <0.001
Fasting Ins (IU/mL) 10(6-14) 7.6 (3.5-15) <0.001
HbA1c (%) 8.6(5.2-12) 6.6 (3.2-13) <0.001
HOMA-IR 4.8(1.66-28.5) 2.37(0.86-32.22) <0.001
Plt (x109/L) 140(50-250) 140 (60-300) 0.018
Cholesterol (mg/dL) 220(160-300) 187 (110-250) <0.001
TG (mg/dL) 212(150-300) 180 (87-220) <0.001
Tumor marker median(range)    
Serum AFP (ng/mL) 115(6-1060) 181(5-560) 0.229
HCV RNA (viral load copies/IU/L) N(%)    
Low (< 100 × 103)n = 21 2(4.8) 19 (32.8) 0.001
Moderate (100-1000 × 103) n = 56 25(59.5) 31 (53.4)  
High (>1000 × 103) n = 23 15(35.7) 8 (13.8) 0.001
Stage of Fibrosis N(%)    
I+II (n = 17) 2 (12) 15 (88) 0.02
III+IV+ V (n = 83) 40 (48) 43 (52)  
  1. ALT, alanine aminotransferase; AST, aspartate aminotransferase, INR, International normalization ratio (for blood clotting); GGT, gammaglutamyl transferase; Glu, glucose; Ins, insulin; HbA1c, glycosylated hemoglobin; HOMA-IR, Homeostasis Model for Assessment of Insulin Resistance; Plt, platelet count; TG, triglycerides; AFP, alpha fetoprotein;